



**For Immediate Release:** September 1, 2010

**Contact:**

Warner Johnston (ESD) | [wjohnston@empire.state.ny.us](mailto:wjohnston@empire.state.ny.us) | 1-800-260-7313

Jola Szubielski (ESD) | [jszubielski@empire.state.ny.us](mailto:jszubielski@empire.state.ny.us) | 1-800-260-7313

**HARRIMAN BUSINESS CENTER TENANT RECEIVES MAJOR GRANT FOR  
KIDNEY DISEASE RESEARCH**

*BREONICS receives 1 of only 10 National Institute of Health grants awarded nationwide*

*\$2.9 million research grant will allow BREONICS, Inc. to proceed with the clinical development of potentially life-saving technology that will increase kidneys available for transplantation*

Empire State Development (ESD) and the Harriman Research and Technology Development Corporation (HRTDC) today announced that BREONICS, INC., a biomedical research firm and the newest tenant in the Harriman Business Center incubator, has been awarded a \$2.9 million research grant from the National Institute of Diabetes and Digestive and Kidney Disease (NIDDK). The funding represents an initial investment from the National Institute of Health's Biomedical Research, Development, and Growth to Spur the Acceleration of New Technologies (BRDG-SPAN) RC3 Pilot Program to demonstrate the clinical and commercial value of BREONICS' new breakthrough technology, which was created to exponentially increase the number of viable kidneys for transplantation. The RC3 grant is the second award made to BREONICS by the National Institutes of Health within the past year. In 2009, BREONICS was awarded \$400,000 for a special emphasis grant by the National Institute for Immunology, Allergy and Infectious Diseases (NIAID) for its immunocloaking technology to protect kidney grafts from rejection.

"We congratulate our newest tenant in the Harriman Business Center, BREONICS, Inc.," said Harriman Research and Technology Development Corporation President and ESD Capital Region Regional Director Peter Wohl. "The company has been working tirelessly towards its goal to provide this cutting edge technology that will have tremendous medical benefits for the public. With the NIH research grant, BREONICS can now take its work to the next level, continuing to grow its research and development initiatives, which is a large focus of ESD's business development efforts. HRTDC and ESD are pleased to support the company's start-up within the Harriman Campus, as BREONICS' focus aligns well with our current redevelopment plans and will help position the Capital Region and New York State as a leader in 21<sup>st</sup> century technology."

“Congratulations to BREONICS for developing cutting edge technology that has a tremendous potential to improve medical outcomes and save lives,” said Congressman Paul Tonko. “This Recovery Act funding will help BREONICS continue their research and move it forward in a way that will help bring this technology to market.”

BREONICS is currently engaged in the research and development of products designed to increase clinical organ transplants. Exsanguinous Metabolic Support (EMS) is BREONICS’ most advanced technology that consists of the solutions and equipment designed to maintain an organ in a metabolically active state while outside of the body. By overcoming the technical barriers that limit organ donor criteria, BREONICS’ EMS technology has the potential to more than double the number of cadaveric kidneys available for transplant each year. Dr. Lauren Brasile, BREONICS’ Chief Scientific Officer and Principal Investigator, has successfully assembled a partnership with three nationally renowned transplantation programs that include the University of Michigan, the Cleveland Clinic and the University of Alabama/Birmingham to support the project.

“The grant being awarded to BREONICS exemplifies the vision that drives HRTDC by supporting a technology-based business model that will help grow our economy and attract jobs to the Capital Region,” said John C. Egan, HRTDC Chairman and New York State Office of General Services Commissioner. “The fact that their research may result in saving the lives of many people waiting for kidney transplants makes it even more important. We are very proud that BREONICS selected this location for their business and we congratulate them on the excellence of their achievement. We look forward to a long partnership with BREONICS as their business continues to grow.”

Albany Mayor Gerald Jennings said: “As Tech Valley continues to expand, I congratulate BREONICS for being awarded this most prestigious grant. Their commitment to medical advances, coupled with their demonstrated allegiance to our community, is truly exemplary of what the Harriman Business model is. New York’s All-America Capital City joins with others to recognize this achievement, as this is yet another tangible example of our City’s importance in the technology arena.”

BREONICS President Ernie Green said: “We are absolutely delighted as the competition for this grant was ferocious, and only 10 were awarded throughout the United States. This award gives us the opportunity to begin transitioning our technology into the clinical arena where we believe it will provide an immense medical and economic benefit.”

HRTDC Vice President Richard Usas said: “Since initially occupying space in the Business Center in January 2010, BREONICS has been continually expanding their research capacity. They are rapidly becoming one of our larger tenants and it is our expectation that with this additional funding they will continue to grow. We are very excited about the company’s presence in the technology sector of the Capital District and the support that HRTDC has been able to provide to this thriving business.”

The Biomedical Research, Development, and Growth to Spur the Acceleration of New Technologies (BRDG-SPAN) Pilot Program (RC3) is supported by funds provided to the NIH under the American Recovery & Reinvestment Act of 2009. The purpose of this pilot program is to address the funding gap between promising research and development (R&D) and transitioning to the market by contributing to the critical funding needed by applicants to move toward ultimate commercialization. The program aims to accelerate the transition of research innovations and technologies toward the development of products or services that will improve human health, help advance the mission of NIH and its Institutes and Centers (ICs), and create significant value and economic stimulus. The program also aims to foster partnerships among a variety of research and development (R&D) collaborators working toward these aims.

BREONICS is a biomedical research and development company headquartered in Albany, New York. BREONICS' focus is to apply its novel bioengineering technologies to create innovative medical products for the clinical organ transplant and tissue replacement markets. BREONICS, Inc. leased lab and office space at the Harriman Business Center incubator in January, occupying 2,500 square feet and housing four employees. The Company intends to increase its space requirement and add new employees as its technology development program expands.

The Harriman Business Center highlights the role of the overall Harriman Campus in stimulating the innovation economy of Tech Valley and New York State. The Harriman Research and Technology Development Corporation is working in close partnership with the University at Albany to build on its leadership in scientific research and technology development as the basis for attracting business to the Harriman Campus. HRTDC, a subsidiary of Empire State Development, is also a founding member of the Business Incubator Association of New York State, a state-level association dedicated to promoting incubation statewide.

According to the National Business Incubation Association, business incubators nurture the development of entrepreneurial companies, helping them survive and grow during the start-up period. These incubators and associated programs provide their client companies with business support services and resources tailored especially to young firms with a goal to create jobs and retain businesses in a community, enhance a community's entrepreneurial climate and build or accelerate growth in a local industry.

Empire State Development is New York's chief economic development agency, committed to being recognized on a global scale as the economic development engine driving job growth, strategic investment and prosperity in New York State. ESD is intent on paving the way for New York State to become the leader of the innovation economy and one of the most business friendly, productive and competitive economic development climates in the world. ESD also oversees the marketing of "I LOVE NY," the State's iconic tourism brand.

###